- Home
- RPRX vs LAD Comparison
RPRX vs LAD Comparison
Compare RPRX & LAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- LAD
- Stock Information
- Founded
- RPRX 1996
- LAD 1946
- Country
- RPRX United States
- LAD United States
- Employees
- RPRX N/A
- LAD N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- LAD Retail-Auto Dealers and Gas Stations
- Sector
- RPRX Health Care
- LAD Consumer Discretionary
- Exchange
- RPRX Nasdaq
- LAD Nasdaq
- Market Cap
- RPRX 11.7B
- LAD 10.0B
- IPO Year
- RPRX 2020
- LAD 1996
- Fundamental
- Price
- RPRX $25.23
- LAD $364.05
- Analyst Decision
- RPRX Strong Buy
- LAD Buy
- Analyst Count
- RPRX 6
- LAD 13
- Target Price
- RPRX $41.67
- LAD $361.38
- AVG Volume (30 Days)
- RPRX 3.2M
- LAD 262.9K
- Earning Date
- RPRX 02-13-2025
- LAD 02-12-2025
- Dividend Yield
- RPRX 3.33%
- LAD 0.58%
- EPS Growth
- RPRX 518.56
- LAD N/A
- EPS
- RPRX 2.55
- LAD 29.30
- Revenue
- RPRX $2,266,003,000.00
- LAD $34,689,000,000.00
- Revenue This Year
- RPRX $12.21
- LAD $17.11
- Revenue Next Year
- RPRX $11.13
- LAD $8.06
- P/E Ratio
- RPRX $9.88
- LAD $12.43
- Revenue Growth
- RPRX N/A
- LAD 14.43
- 52 Week Low
- RPRX $24.05
- LAD $243.00
- 52 Week High
- RPRX $31.66
- LAD $405.68
- Technical
- Relative Strength Index (RSI)
- RPRX 43.88
- LAD 44.79
- Support Level
- RPRX $24.05
- LAD $354.27
- Resistance Level
- RPRX $25.28
- LAD $385.93
- Average True Range (ATR)
- RPRX 0.55
- LAD 8.90
- MACD
- RPRX 0.00
- LAD -3.73
- Stochastic Oscillator
- RPRX 46.46
- LAD 30.89
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About LAD Lithia Motors Inc.
Lithia Motors is a retailer of new and used vehicles and related services. The company offers over 50 brands of vehicles at nearly 500 stores globally across the US, Canada, and UK. The company has expanded largely through the acquisition of dealerships in smaller regional markets but now seeks to grow in any part of the US and we expect more deals over time in the US and, at times, abroad. Annual revenue in 2023 was $31 billion and we see over $50 billion possible in a few years. The US was 90% of 2023 revenue and the UK second at 6%, the latter should rise to around 20% with the 2024 Pendragon acquisition. In 2023, new-car sales were about 49% of total revenue. Lithia was founded in 1946, went public in 1996, and is the largest US auto dealer. It is based in Medford, Oregon.